Roche pulls an­oth­er ma­jor piece out of the wob­bly Alzheimer's jen­ga, shut­ter­ing crenezum­ab PhI­I­Is

When AC Im­mune an­nounced two years ago that its part­ners at Genen­tech is launch­ing a sec­ond Phase III for its Alzheimer’s drug, CEO An­drew Pfeifer tout­ed crenezum­ab as a “dis­tinct” hope amid dis­ap­point­ing re­sults of oth­er an­ti-amy­loid be­ta ther­a­pies, giv­en at high­er dos­es and tar­get­ing ear­li­er stages of the dis­ease.

To­day crenezum­ab has be­come a big dis­ap­point­ment it­self — mark­ing an­oth­er promi­nent fail­ure in a frus­tra­tion-prone field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER